BREAKING NEWS
India closer to building world’s biggest nuclear plant: EDF
Maker of ‘Shashank’ denies in HC film based on Sushant Singh Rajput
SC intervention in COVID-19 management uncalled for: Congress
Father attended Kumbh but can’t say he caught the virus there: Shravan Rathod’s son
Leaving with satisfaction, I did my best: CJI Bobde
Escort oxygen cylinders with Army vehicles: Kejriwal at PM-CM meet
Mangaluru: Fire breaks out at MCC Bank
COVID-19: Over 3.32 lakh fresh cases in India in single day, record 2,263 fatalities
Fake news of Sumitra Mahajan’s death goes viral; Shashi Tharoor tweets condolence
I beg govt to make arrangements for last rites of COVID victims in dignified manner: HDK
Karnataka to purchase 1 crore doses of Covishield vaccine for Rs 400 crore
Additional allocation of 25,000 Remdesivir vials for Karnataka, says Sadananda Gowda
Oxygen will last 2 hours; 25 Covid-19 patients have died in last 24 hrs at Delhi’s Sir Ganga Ram Hospital
Covid-19: Canada bans flights from India and Pakistan for 30 days
13 COVID-19 patients die in Maha hospital fire
Bharat Biotech’s Covaxin 81 pc efficient in Phase 3 trials
PTI, Mar 3, 2021, 7:25 PM IST
New Delhi: Vaccine major Bharat Biotech on Wednesday said its COVID-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81 per cent in Phase 3 clinical trials.
The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement.
”Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants,” Bharat Biotech Chairman and Managing Director Krishna Ella said.
Covaxin demonstrates a high clinical efficacy trend against COVID-19 but also significant immunogenicity against the rapidly emerging variants, he added.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Covaxin and Oxford-AstraZeneca’s Covishield are the two vaccines that are being administered in the country.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Delhi puts in request for ”Oxygen Express”; demand likely to be met from Rourkela
Bihar’s ”oxygen man” ray of hope for critical COVID-19 patients
India’s COVID-19 graph may peak at 33-35 lakh active cases by May 15, say IIT scientists
TN CM writes to Modi, seeks 20 lakh doses of Covid vaccine from Centre
Govt issues revised clinical guidance for management of COVID-19 patients
MUST WATCH
Udayavani 23-April-2021 News Bulletin
D.K. district administration will be able to deal with the situation adequately for the next 15 days: Dr. Rajendra K.V
Mangaluru: 1 arrested in Surathkal animal cruelty case
Saligrama town Panchayat Dumping Yard protest
Fire broke out at Mangaluru Catholic Co-operative Bank
Latest Additions
Airlift oxygen, give adequate vaccines, allow Remdesivir imports: Thackeray tells PM
Would have taken part in COVID meeting between PM Modi, CMs had I been invited: Mamata
India closer to building world’s biggest nuclear plant: EDF
States must jointly negotiate uniform Covid-19 vaccine price with manufacturers, says Chidambaram
Mangaluru Police arrest history sheeter for conspiring to commit robbery, murder